WA
IONS icon

Waddell & Associates’s Ionis Pharmaceuticals IONS Stock Holding History

Waddell & Associates’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-10,042
Closed -$456K – 158
2023
Q3 		$456K Hold
10,042
– – 0.07% 85
2023
Q2 		$412K Hold
10,042
– – 0.06% 94
2023
Q1 		$359K Hold
10,042
– – 0.06% 100
2022
Q4 		$379K Hold
10,042
– – 0.06% 91
2022
Q3 		$444K Hold
10,042
– – 0.09% 73
2022
Q2 		$372K Buy
+10,042
New +$379K 0.08% 83
2021
Q3 		– Sell
-10,042
Closed -$401 – 122
2021
Q2 		$401 Buy
+10,042
New +$393K 0.06% 75

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

Waddell & Associates's IONS Position: Q4 2023 in Review

Waddell & Associates sold out of Ionis Pharmaceuticals (IONS) in Q4 2023, closing a stake of 10,042 shares — an estimated $456K sold.

Waddell & Associates first reported a position in IONS in Q2 2021 and held it in 7 quarters. The position peaked at $456K in Q3 2023. 363 funds tracked by Wall St. Rank hold IONS as of Q4 2023.

  • Waddell & Associates reported no remaining Ionis Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Waddell & Associates sold 10,042 Ionis Pharmaceuticals shares in Q4 2023, an estimated $456K.
  • Waddell & Associates first reported a position in Ionis Pharmaceuticals in Q2 2021 and held it in 7 quarters.
  • Waddell & Associates's Ionis Pharmaceuticals position peaked at $456K in Q3 2023.
  • 363 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q4 2023.

Based on Waddell & Associates's 13F filing for Q4 2023, filed 14 Feb 2024.